You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test is designed to detect the SARS-CoV-2 nucleocapsid gene in nasopharyngeal, oropharyngeal, nasal, and midturbinate nasal swab samples.
Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.
Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.
A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.
A Columbia University doctor is seeking to use nanopore sequencing to uncover the cause of recurrent miscarriages, reports NBC News.
An analysis of cases and controls from South Africa's Xhosa population pointed to private, damaging mutations in genes expressed in the brain.
The partners are studying wild-type cardiac amyloidosis, a rare condition characterized by the accumulation of abnormal proteins in the heart.
Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
A study group eager to learn about genetic testing online was not won over by videos produced by academics without communication expertise.
The project is part of the Human Cell Atlas, an international effort to build reference maps of all human cell types using single-cell analysis.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.